[not BIT specific but I posted this on the PRR thread and someone there requested I post it here too so I assume it's relevant to BIT thread, similar to PRR]
http://www.fool.com/investing/general/2011/10/28/invest-in-biotechs-going-after-unmet-needs.aspx
By Brian Orelli | More Articles
October 28, 2011 | Comments (0)
Wow!
Is there really any other way to describe the launch of Vertex Pharmaceuticals' (Nasdaq: VRTX ) hepatitis C drug Incivek?
We got a first peek at the launch in the second quarter, but that was only six weeks ago. The third quarter offered the first look at a full quarter of revenue. And what a quarter it was: $420 million in net sales of its new hepatitis C drug. Assuming nothing surprising pops up, Incivek will reach the magic $1 billion blockbuster status in its first 12 months on the market. That's easily the most successful launch in recent memory. Dendreon (Nasdaq: DNDN ) , Acorda Therapeutics (Nasdaq: ACOR ) , and Avanir Pharmaceuticals (Nasdaq: AVNR ) could learn a thing or two.
The unmet need of hepatitis C patients is a big reason for the successful launch of Incivek. The current treatments -- Roche's Pegasys and Merck's (NYSE: MRK ) PegIntron -- only cure about half of the patients they treat. Adding Incivek increases that number substantially and allows for a shorter duration of Pegasys or PegIntron, which is helpful given the nasty side effects of those drugs.
Keep in mind that unmet need may be necessary for a launch this successful, but it isn't sufficient to get you there. Incivek still had to post better cure rates than Merck's second-generation drug, Victrelis; if their efficacy had been similar, I'm not sure we'd be drooling over Incivek sales right now. Just look at Human Genome Sciences' (Nasdaq: HGSI ) Benlysta; it's the first new lupus treatment in 50 years, but sales last quarter were just $18.8 million, partially because doctors aren't convinced by the efficacy.
At a market cap topping $8.5 billion, there are still a lot of Incivek sales built in to Vertex's valuation. To grow further, Vertex has to keep growing sales of Incivek and gain approval for its cystic fibrosis drug Kalydeco next. A successful launch of that product would certainly help. But would you expect anything less? Cystic fibrosis is another unmet medical need.
- Forums
- ASX - By Stock
- BIT
- invest in biotechs going after unmet needs
invest in biotechs going after unmet needs
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
3.9¢ |
Change
0.001(2.63%) |
Mkt cap ! $35.18M |
Open | High | Low | Value | Volume |
3.9¢ | 4.1¢ | 3.8¢ | $65.43K | 1.670M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 46055 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.9¢ | 59151 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 46055 | 0.038 |
3 | 453512 | 0.037 |
4 | 365000 | 0.036 |
6 | 753214 | 0.035 |
3 | 146000 | 0.033 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 59151 | 1 |
0.041 | 124099 | 2 |
0.042 | 157042 | 2 |
0.043 | 102000 | 1 |
0.044 | 140000 | 1 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online